Norwood Hamilton, MD
Nephrology · North Charleston, SCNPI 1831160431
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Outset Medical Inc at 50.8% of the total. Reporting peaked in 2019 at $2,813 and has fallen 76.9% since, to $650 in 2025.
Across 126 payments — averaging $42.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$3K
- Vifor Pharma, Inc.$685
- Otsuka America Pharmaceutical, Inc.$244
- Calliditas Therapeutics US Inc.$211
- Novartis$197
- AstraZeneca$171
- plus $1K from 22 others
What the payments were for
- Consulting fees$2,67350%
- Food & beverage$2,40545%
- Education$2184%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 3 | $2,690 |
| Vifor Pharma, Inc. | 44 | $685 |
| Otsuka America Pharmaceutical, Inc. | 9 | $244 |
| Calliditas Therapeutics US Inc. | 5 | $211 |
| Novartis | 9 | $197 |
| AstraZeneca(2 entities) | 9 | $171 |
| Travere Therapeutics, Inc. | 8 | $155 |
| Amgen(2 entities) | 6 | $114 |
| Mallinckrodt Hospital Products Inc. | 5 | $114 |
| Bard Peripheral Vascular, Inc. | 1 | $105 |
| Novo Nordisk | 4 | $103 |
| Ardelyx, Inc. | 2 | $56 |
| Akebia Therapeutics Inc | 2 | $55 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $40 |
| Boehringer Ingelheim | 2 | $40 |
| Bayer | 2 | $36 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| GSK | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$123
How this compares
$5,296 in reported general payments places this provider in the 75th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 34 | $94,643 |
| AuryxiaFerric Citrate | 22 | $38,555 |
| FarxigaDapagliflozin Propanediol | 25 | $24,070 |
| Sevelamer Carbonate | 59 | $22,055 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $12,636 |
| Calcium Acetate | 39 | $3,012 |
| Clonidine | 11 | $861 |
| Valsartan | 26 | $448 |
| Furosemide | 46 | $266 |
| Amlodipine Besylate | 82 | $262 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $252 |
| Nifedipine ErNifedipine | 14 | $246 |
| Losartan Potassium | 21 | $227 |
| Lisinopril | 20 | $185 |
| Spironolactone | 21 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $34 | $94,64334 claims |
| Akebia Therapeutics IncAuryxia | $55 | $38,55522 claims |
| AstraZenecaFarxiga | $171 | $24,07025 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $17 | $44826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 nephrology providers in South Carolina.
Other nephrology in North Charleston
- Benjamin WeathersbyNorth Charleston$14K
- Bradley KalinskyNorth Charleston$11K
- Richard BrowderNorth Charleston$6K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.